Donglin Xia

Dr. Donglin Xia


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2020 in Nano Letters
Verified
Journal Article
Closed access
HHHao Huang
Hao Huang
CZChao Zhang
Chao Zhang
XWXiaolin Wang
Xiaolin Wang
JSJinsong Shao
Jinsong Shao
CCChao Chen
Chao Chen
DXDonglin Xia
Donglin Xia

7 September 2022 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
YLYi Li
Yi Li
AWAnqi Wu
Anqi Wu
LCLin Chen
Lin Chen
ACAiting Cai
Aiting Cai
YHYuhao Hu
Yuhao Hu
FWFeng Wang
Feng Wang
Background: Circular RNA (circRNA) is crucial to the progression of hepatocellular cancer (HCC). In addition, Mitochondrial calcium uniporter regulatory factor 1 (MCUR1) is commonly overexpressed in HCC to increase cellular ATP levels. Due to the highly aggressive characteristics of HCC, it is essential to identify new diagnostic biomarkers and therapeutic targets that may facilitate the diagnosis of HCC and the development of effective anti-HCC treatments. Methods: A series of in vitro and in vivo experiments were undertaken to investigate the biological importance and underlying mechanisms of circ_0000098 in HCC. Results: The expression of circ_0000098 was higher in HCC tissues compared to paired adjacent tissues. According to the receiver-operating characteristic curves, circ_0000098 functioned as a potential diagnostic tumor marker in HCC. Our experiments indicated that circ_0000098 served as a key oncogenic circRNA to increase HCC cell proliferation and invasion in vitro and HCC progression in vivo. Furthermore, mechanistic investigation demonstrated that by sequestering miR-383 from the 3′-UTR of MCUR1, circ_0000098 positively regulated MCUR1 expression in HCC cells and finally promoted HCC progression. On the other hand, inhibiting circ_0000098 in HCC cells could diminish doxorubicin (DOX) resistance by decreasing P-glycoprotein (P-gp, MDR1) expression and intracellular ATP levels. Either downregulation of MCUR1 or overexpression of miR-383 improved DOX sensitivity in HCC cells. Subsequently, a short hairpin RNA targeting circ_0000098 (referred to as sh-1) and doxorubicin (DOX) were encapsulated into platelets (PLTs), referred to as DOX/sh-1@PLT. Activated DOX/sh-1@PLT through HCC cells resulted in the creation of platelet-derived particles that were capable of delivering the DOX/sh-1 combination into HCC cells and promoting intracellular DOX accumulation. Furthermore, our in vivo experiments showed that DOX/sh-1@PLT can effectively reduce P-gp expression, promote DOX accumulation, and reverse DOX resistance. Conclusions: Our results demonstrated that circ_0000098 is an oncogenic circRNA that promotes HCC development through the miR-383/MCUR1 axis and targeting circ_0000098 with DOX/sh-1@PLT may be a promising and practical therapeutic strategy for preventing DOX resistance in HCC.

1 January 2022 in Journal of Controlled Release
Verified
Journal Article
Closed access
JSJinsong Shao
Jinsong Shao
LFLingzi Feng
Lingzi Feng
QZQingyu Zhao
Qingyu Zhao
CCChao Chen
Chao Chen
JLJia Li
Jia Li
DXDonglin Xia
Donglin Xia

13 March 2024 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
TZTingting Zuo
Tingting Zuo
XLXiaodie Li
Xiaodie Li
XMXuan Ma
Xuan Ma
YZYe Zhang
Ye Zhang
XLXueru Li
Xueru Li
HCHuijun Cheng
Huijun Cheng
Photodynamic therapy (PDT), a promising treatment modality, employs photosensitizers to generate cytotoxic reactive oxygen species (ROS) within localized tumor regions. This technique involves administering a photosensitizer followed by light activation in the presence of oxygen (O2), resulting in cytotoxic ROS production. PDT’s spatiotemporal selectivity, minimally invasive nature, and compatibility with other treatment modalities make it a compelling therapeutic approach. However, hypoxic tumor microenvironment (TME) poses a significant challenge to conventional PDT. To overcome this hurdle, various strategies have been devised, including in-situ O2 generation, targeted O2 delivery, tumor vasculature normalization, modulation of mitochondrial respiration, and photocatalytic O2 generation. This review aims to provide a comprehensive overview of recent developments in designing tumor-oxygenated nanomaterials to enhance PDT efficacy. Furthermore, we delineate ongoing challenges and propose strategies to improve PDT’s clinical impact in cancer treatment.

1 January 2024 in Theranostics
Verified
Journal Article
Open access
PDF file
JTJiale Tian
Jiale Tian
MGMingde Gao
Mingde Gao
JZJinfeng Zhu
Jinfeng Zhu
HXHaifei Xu
Haifei Xu
HJHao Ji
Hao Ji
XWXiaolin Wang
Xiaolin Wang
The regulation of immunosuppressive microenvironments in tumors through targeted drug delivery shows promise for immunochemotherapy in bladder cancer. Drawing inspiration from stealth tactics, a nano-vehicle camouflaged with platelets (PLTs) was developed to enable precise delivery and trigger pyroptosis for tumor immunotherapy.

16 January 2025 in Nanomaterials
Verified
Journal Article
Open access
PDF file
CCChao Chen
Chao Chen
越许越 许
越 许
HMHui Meng
Hui Meng
HBHongyi Bao
Hongyi Bao
Yong HuYong Hu
Yong Hu
DXDonglin Xia
Donglin Xia
Nano-oncologic vaccines represent a groundbreaking approach in the field of cancer immunotherapy, leveraging the unique advantages of nanotechnology to enhance the effectiveness and specificity of cancer treatments. These vaccines utilize nanoscale carriers to deliver tumor-associated antigens and immunostimulatory adjuvants, facilitating targeted immune activation and promoting robust antitumor responses. By improving antigen presentation and localizing immune activation within the tumor microenvironment, nano-oncologic vaccines can significantly increase the efficacy of cancer immunotherapy, particularly when combined with other treatment modalities. This review highlights the mechanisms through which nano-oncologic vaccines operate, their potential to overcome existing limitations in cancer treatment, and ongoing advancements in design. Additionally, it discusses the targeted delivery approach, such as EPR effects, pH response, ultrasonic response, and magnetic response. The combination therapy effects with photothermal therapy, radiotherapy, or immune checkpoint inhibitors are also discussed. Overall, nano-oncologic vaccines hold great promise for changing the landscape of cancer treatment and advancing personalized medicine, paving the way for more effective therapeutic strategies tailored to individual patient needs.